As Britain Brexits from the EU, it’s going to be more important than ever that the UK convincingly demonstrates to the world that it embraces new innovations.
The ABPI have responded today to an announcement by the Department of Health & Social Care who have published a 12 week consultation seeking views from interested parties on the recommendations in the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP).
The Association of the British Pharmaceutical Industry (ABPI) has responded to a Cochrane Collaboration publication, which has assessed all the drug company trials of the breakthrough hepatitis C treatments.
A new report by the Swedish Institute for Health Economics (IHE) has found that more people than ever across Europe are now surviving cancer.
The Association of the British Pharmaceuticals Industry (ABPI) has responded to the International Comparisons of Health Technology Assessment report, published today, and also addressed claims that patients are being denied life-prolonging treatments for cancer.
"We want the best for all cancer patients. The role of the Cancer Drugs Fund is to fund medicines that have been rejected or not approved by NICE in order to ensure that NHS patients have improved access, as they do in other EU countries. We share the desire of the Public Accounts Committee to...
The Association of the British Pharmaceutical Industry (ABPI) broadly welcome the Public Accounts Committee report on NHS England Specialised Services. The recommendations urgently call for NHS England to become much more transparent in both its operation (including in regard to publication of...
The Association of the British Pharmaceutical Industry (ABPI) has responded to the rollout of the new Cancer Drugs Fund (CDF) that has gone live today with an annual fixed budget of £340 million in 2016/17.
"The ABPI is disappointed by today's decision by NHS England that it will continue to push ahead with largely unchanged proposals for a new Cancer Drugs Fund. This carries the very real risk of significantly setting back patient access to cancer medicines, now and for the foreseeable future."
The ABPI welcomes this important report from Lord Warner’s Short Life Commission into the future of the commissioning and delivery of specialised services within England.